| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; 2 Department of Epidemiology, Shanghai Cancer Institute, Shanghai, People’s Republic of China; and 3 Department of Epidemiology and Biostatistics, Norman J. Arnold School of Public Health, University of South Carolina, Columbia, South Carolina
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
T) and 1298 (AC), resulting in allozymes with decreased activity. We evaluated these two common polymorphisms and their effects on the folate intake and breast cancer risk association in a population-based case-control study of 1144 breast cancer cases and 1236 controls using a PCR-RFLP-based assay. All subjects completed in-person interviews, which included a food frequency questionnaire. Unconditional logistic regression models were used to calculate odds ratios and their 95% confidence intervals, after adjusting for potential confounding factors. Cases and controls were similar in the distribution of MTHFR polymorphisms at codons 677 (41.4% cases and 41.8% controls carried the T allele) and 1298 (17.6% cases and 17.5% controls carried the C allele). An inverse association of breast cancer risk with folate intake was observed in all genotype groups, particularly among subjects with the 677TT genotype. Compared with those with the 677CC genotype and high folate, the adjusted odds ratios (95% confidence intervals) associated with low folate intake were 1.94 (1.15–3.26), 2.17 (1.34–3.51), and 2.51 (1.37–4.60) for subjects who had CC, CT, and TT genotypes (p for interaction, 0.05). No modifying effect of A1298C genotypes on the association of folate intake with breast cancer risk was observed. Results of this study suggest that the MTHFR C677T polymorphisms may modify the association between dietary folate intake and breast cancer risk. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Two common polymorphisms in the MTHFR gene have been characterized (6
, 7)
. The 677C T polymorphism codes for an alanine to valine substitution in the N-terminal catalytic domain and results in an allozyme with 
65% and 30% of the wild-type homozygote activity for heterozygotes and homozygotes of the variant allele, respectively (6
, 8)
. The A C polymorphism at nucleotide 1298 codes for an alanine to glutamine substitution in the C-terminal regulatory domain (7)
. Individuals homozygous for the 1298C allele have approximately the same enzyme activity as those heterozygous for the 677T allele (7
, 8)
.
The C677T polymorphism has been examined in relation to several cancers (2 , 9) . In most studies of colorectal neoplasms, the MTHFR 677TT genotype has been associated with an overall reduction in risk, reduced risk among those with higher intakes of folate (10, 11, 12, 13) , or increased risk among those with lower folate intakes (13, 14, 15) . MTHFR has not been as well studied in relation to breast cancer risk. Only three small studies have evaluated the association between MTHFR genotype and breast cancer (16, 17, 18) . The results from these studies have been inconsistent. Only one study assessed both the C677T and A1298C polymorphisms and their possible joint effect with folate intake (18) . However, in that study, only 60 cases were included. We reported recently that folate intake was inversely associated with breast cancer risk in a large population-based, case-control study among Chinese women in Shanghai (19) . In an extension of these results, we investigated whether this association may be modified by MTHFR genotypes.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Subjects.
All incident breast cancer cases newly diagnosed during the study period and meeting the eligibility criteria were identified through a rapid case-ascertainment system supplemented by the Shanghai Cancer Registry and were approached for participation in the study. Eligibility criteria for the study were as follows: 25–64 years of age, resident of urban Shanghai, no previous history of any cancer, and alive at the time of interview. In all, 1602 eligible cases were identified, of whom 1459 (91.1%) completed in-person interviews. The median interval from cancer diagnosis to the in-person interview was 64 days. With the exception of a breast cancer diagnosis, controls had inclusion criteria identical to those of the cases and were frequency matched on age (5 years intervals) to the expected age distribution of the cases. In all, 1724 eligible controls were randomly selected from the Shanghai Resident Registry. Of these, 1556 (90.3%) completed in-person interviews.
Data and Biological Sample Collection.
All subjects completed an in-person interview that used a structured questionnaire and incorporated anthropometric measurements. Dietary intakes were assessed using a 76-item food frequency questionnaire (FFQ). In a recent validation study of the FFQ among 200 women, we found that the FFQ captured >86% of food intake in Shanghai (21)
. Each subject was asked about the frequency that a specific food was eaten (daily, weekly, monthly, yearly, or never), followed by a question on the amount typically eaten. Dietary intakes of total folate and folate cofactors were derived from the FFQ by summing the product of the micronutrient content of each food item, usual portion eaten, and frequency of consumption. Because of the lack of folate data in the Chinese food composition database, an identical (82%) or equivalent (17%) item from the United States Department of Agriculture food composition database was used to determine micronutrient level (19)
. To assess the comparability of the Chinese and United States Department of Agriculture food composition databases, we evaluated the correlation of three other water-soluble vitamins (vitamin C, riboflavin, and niacin) and found excellent correlation; all Pearson correlation coefficients were r 
0.91 or higher, providing ancillary support for the validity of derived folate data in this study. In a validation study of the FFQ among 200 women, the FFQ was administered twice in a year and Pearson correlation for folate was r = 0.36. Blood samples were collected from 1193 (82%) cases and 1310 (84%) controls and used in this study for genotyping assays.
Laboratory Methods.
Genomic DNA was extracted from blood samples with the Puregene DNA isolation Kit (Gentra Systems, Minneapolis, MN) following the protocol of the manufacturer. Genotyping for the MTHFR C677T and A1298C polymorphisms were performed using PCR-RFLP methods reported by Frosst et al. (6)
and Weisberg et al. (7)
, with minor modifications. The primers for C677T analysis were 5'-TGAAGGAGAAGGTGTCTGCGGGA-3' (exonic) and 5'-AGGACGGTGCGGTGAGAGTG-3' (intronic). The primers for A1298C analysis were 5'-GGGAGGAGCTGACCAGTGCAG-3' and 5'-GGGGTCAGGCCAGGGGCAG-3'. The PCR reactions were performed in a Biometra TGradient Thermocycler. Each 20 µl of PCR mixture contained 10 ng DNA, 1x PCR buffer [50 mM KCl, 10 mM Tris-HCl (pH 9.0)], 1.5 mM MgCl2, 0.2 mM each of deoxynucleoside triphosphate, 0.5 mM of each primer, and 1 unit of TaqDNA polymerase. The reaction mixture was initially denatured at 94°C for 3 min. For C677T polymorphisms, PCR was performed in 30 cycles of 94°C for 45 s, 65°C for 45 s, and 72°C for 45 s. For A1298C polymorphisms, PCR was performed in 35 cycles of 94°C for 45 s, 65°C for 45 s, and 72°C for 45 s. The PCR was completed by a final extension cycle at 72°C for 7 min.
For C677T polymorphisms, each PCR product (10 µl) was digested with 10 units of Hinf I at 37°C for 3 h. The DNA fragments were then separated using 3% agarose gel and detected by ethidium bromide staining. The CT substitution at nucleotide 667 creates a Hinf I digestion site. The PCR product (198 bp) with the T allele was digested to two fragments (175 bp and 23 bp), whereas the PCR product with wild-type C allele cannot be cut by Hinf I. For A1298C polymorphisms, each PCR product (10 µl) was digested with 5 units of Fnu4H I at 37°C for 3 h, followed by 3% agarose gel electrophoresis and ethidium bromide staining. The AC substitution at nucleotide 1298 creates a Fnu4H I site. The PCR product (138 bp) with C allele was digested to two fragments (119 bp and 19 bp), whereas the PCR product with wild-type A allele cannot be cut by Fnu4H I.
Quality-control samples were included in various batches of samples assayed for the polymorphisms. The consistency rate was 98.5% in 119 quality-control samples that were repeated in the genotyping assays with their identities unknown to laboratory staff. Excluding a few subjects for whom sufficient DNA was not available or for whom the genotyping assay failed, genotyping data were obtained from 1112 cases and 1160 controls for C677T and 1121 cases and 1208 controls for A1298C polymorphisms. Because few women in the study consumed alcohol, a factor that may increase folate requirements, and because the data on the folate content of vitamins were not available, all analyses involving folate or its cofactors were limited to the cases (92.0%) and controls (91.1%) who were known not to consume alcohol regularly and not to take vitamin supplements.
Data Analysis.
Odds ratios (ORs) were used to measure the association of breast cancer risk with MTHFR genotype. Unconditional logistic regression models were used to obtain maximum likelihood estimates of the ORs and their 95% confidence intervals (CIs), after adjusting for potential confounding variables. Risk factors previously identified as having an independent association with breast cancer were controlled in all models. These included age, personal history of fibroadenoma, age at first live birth, physical activity, waist-to-hip ratio, and daily meat intake. Age was included as a continuous variable throughout, and categorical variables were treated as indicator variables in the model. Quartile and tertile distributions of dietary intakes among controls were used to categorize all dietary intake variables. In the analyses including dietary factors, energy adjustment was performed using the standard multivariate method (22)
. Tests for trend were performed by entering categorical variables as continuous. Stratified analyses were used to evaluate the potential modifying effect of age, menopausal status, and folate and folate cofactor intakes on breast cancer risk associated with MTHFR genotypes and of MTHFR genotypes on breast cancer risk associated with folate intake. Tests for multiplicative interaction were done by including multiplicative variables in the logistic model and performing the likelihood ratio test. All statistical tests were based on two-sided probabilities using SAS, Version 8.2 (SAS Institute, Inc., Cary, NC).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. Cases were, in general, more highly educated, more likely to have a history of fibroadenoma, younger at menarche, older at first live birth and menopause, less likely to be physically active, and more likely to have a higher body mass index and waist-to-hip ratio than controls. Cases also had higher average daily intakes of animal foods, methionine, and vitamin B6 and lower average daily intake of folate than controls.
|
. The frequencies of the 677T and 1298C alleles were 0.41 and 0.18, respectively, among the controls. These were virtually identical to the frequency among the cases. Among the controls, the distributions of the MTHFR genotypes did not differ from the predicted distribution under Hardy-Weinberg equilibrium (P = 0.44 for the C677T polymorphisms and P = 0.58 for the A1298C polymorphisms). Risk of breast cancer did not differ statistically for the C677T or A1298C genotypes or for their combination. Similar associations were observed in analyses stratified by age and menopausal status (data not shown in table).
|
. Low intake of folate was associated with an increased risk of breast cancer among all genotypes, particularly subjects with the TT genotype (OR = 2.51; 95% CI: 1.37–4.60) There was a significant multiplicative interaction between folate intake and C677T polymorphism in relation to breast cancer risk (P = 0.05). Elevated ORs were observed to be associated with folate intake regardless of A1298C genotype, although the trend was statistically significant in only the AA group. To examine further the C677T association, analyses were restricted to 1298AA individuals because of a small sample size for the AC and CC genotypes. Again, low intake of folate was associated with increased risk for all genotypes, and the increased risk was greatest among those with 677TT genotype (OR = 2.16, 95% CI: 1.09–4.28, p for trend = 0.002, p for interaction = 0.06). There was a suggestive reduced risk associated with the TT genotype among those with high folate intake, although the OR was not statistically significant.
|
, after stratifying by folate cofactor intake. With the exception of the high vitamin B6 stratum, low folate intake was associated with an elevated risk of breast cancer, and the association appeared stronger among subjects with the TT genotypes. None of the tests for multiplicative interactions, however, was statistically significant, perhaps because of a small sample size in these stratified analyses.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
MTHFR polymorphisms have not been adequately investigated in relation to breast cancer risk. Only three previous small studies have examined MTHFR polymorphisms and breast cancer risk (16, 17, 18) . In the first, a study among Jewish women, MTHFR C677T genotype was determined in 491 women with sporadic (n = 355) or hereditary (n = 136) breast and/or ovarian cancer and in 69 asymptomatic BRCA1/2 mutation carriers (16) . The prevalence of the T allele was not significantly different between sporadic cases and the asymptomatic carriers, women diagnosed at a young and older age, and BRCA1/2 carriers with and without cancer. The prevalence of the T allele was more frequent among women with bilateral breast cancer or with both breast and ovarian cancers than among women with only unilateral breast cancer. In the second study, a hospital-based, case-control study among postmenopausal Caucasian women (149 cases and 171 controls), it was reported that the MTHFR 677T (val) allele was more prevalent in cases than controls (17) , which is in contrast to the results from the third case-control study conducted in the United Kingdom (62 cases, 66 controls), the only previous study that reported risk of breast cancer associated with both the C677T and A1298C polymorphisms (18) . The British study reported breast cancer risk was reduced among those homozygous for the 677T allele (OR = 0.39; 95% CI: 0.12–1.24) or 1298C allele (OR = 0.24; 95% CI: 0.06–0.97). However, no modifying effect of the MTHFR C677T genotype was noted on the association between folate intake and breast cancer risk. There was some evidence of a joint association of folate and the A1298C genotype, but the sample size was not large enough to examine this association.
We did not find an overall reduced risk of breast cancer associated with MTHFR 677TT or 1298CC genotypes, which is not consistent with the British study of breast cancer (17) and some of the previous studies for other cancers. Two of three case-control studies of colorectal cancer and the MTHFR C677T polymorphism observed an overall reduction in risk associated with the TT genotype (10 , 11) , as did studies of oral cancer (23) and adult acute lymphocytic leukemia (24) . We also found a similar weak association among women with high intake of folate and folate cofactors. However, other studies of colorectal cancer (12) , colorectal adenoma (13 , 14 , 25) , gastric cancer (9) , lung cancer (26) , and acute myeloid leukemia (24) found no association or an increased risk of cancer for individuals with the TT genotype. Our observation for a stronger inverse association of folate intake and breast cancer risk among women with the TT genotype is supported by the majority of studies examining a similar association for other cancers (10, 11, 12 , 14 , 15 , 23) , and is consistent with the role of folate in breast carcinogenesis. We, and others, have previously found a decreased risk of breast cancer among those with high intake level of folate (19 , 27, 28, 29, 30, 31, 32, 33) . Low folate intake is associated with an increased misincorporation of uracil and chromosome breaks (34 , 35) and aberrant DNA methylation (35 , 36) . The critical factor in breast carcinogenesis may be an appropriate balance between the availability of for DNA methylation and 5,10-methylene-S-adenosylmethioninetetrahydrofolate for DNA synthesis. It is plausible that individuals with the 677TT genotype are particularly susceptible to the carcinogenic consequences of folate insufficiency. This genotype, in the presence of low folate, is associated with higher levels of homocysteine, lower levels of methylated folates and, therefore, reductions in genomic DNA methylation (37 , 38) . Our finding for a positive association of C677T genotype with low folate intake (OR = 2.51, 95% CI: 1.37–4.60) appears to support this notion. Conversely, in folate-replete conditions, the availability of 5,10-methylenetetrahydrofolate for nucleotide synthesis may be adequate or increased for these individuals because of the genetically determined decreased activity of MTHFR. This could explain the lower risk of this genotype among those with high folate levels in this (OR = 0.70, 95% CI: 0.40–1.23 for 677TT) and other studies (10 , 12 , 14 , 15) . Therefore, the effect of MTHFR on breast cancer risk in a particular population may depend on the intake level of folate in that population. With increased folic acid fortification in the United States population, the general intake of folate may be higher than that from the Chinese, whose folate intake is primarily obtained from unfortified diets. This may explain, in part, the overall absence of association of MTHFR genotype with breast cancer risk in our study.
The relationship between folate metabolism and carcinogenesis is likely to be a complex biological sum of genetic and nutritional differences. In our study, the association of folate and breast cancer risk was similar for all genotypes when intakes of vitamin B12, B6, or methionine were low. Vitamin B12, vitamin B6, and methionine all have important roles in one-carbon metabolism; vitamin B12 is a cofactor for the transfer of the methyl group from folate to methionine, vitamin B6 is a coenzyme for the formation of 5,10-methylene-5,10-methylenetetrahydrofolate and the catabolism of homocysteine, and methionine is the precursor for S-adenosylmethionine. It is possible that below a certain intake threshold of vitamin B12 and methionine, the effect of MTHFR C677T genotype or folate intake is reduced or negated and that once this threshold is surpassed, both folate and MTHFR genotype have a greater impact on breast cancer risk. The inverse association with breast cancer risk among those with a high vitamin B6 intake was unexpected and cannot be readily explained by the above rationale. This finding needs to be re-evaluated in future studies.
As with any case-control study, the potential for selection and recall biases must be considered. However, selection bias is unlikely to be a major issue in this study; both cases (91%) and controls (90%) had very high participation rates. Not only did this study have a high participation rate, it also had a high blood collection rate (>80%). Although it is possible that cases and controls may have had differentially recalled intakes of foods that contributed to the nutrients in this study, fruit and vegetable intake, the major contributors to folate, methionine, and vitamin B6 intakes, did not significantly differ between cases and controls. Approximately 50% of cases were interviewed within 15 days of diagnosis and the majority (80%) were interviewed within 4 months, thus reducing potential recall bias attributable to dietary change related to a diagnosis of cancer. In addition, recall of diet would unlikely be related to MTHFR genotype and, therefore, could not account for the associations we observed in this study. Additionally, misclassification in the assessment of folate intake may have occurred from using the Unites States Department of Agriculture food composition database. However, any such misclassification would be nondifferential between cases and controls and would usually result in a bias toward the null. Confounding by other factors is always a concern in epidemiological studies. We observed little confounding when we carefully adjusted for known risk factors. Although it is possible that residual confounding may still exist, for example, from dietary factors not considered in this study, additional factors are not likely to explain the strength of the observed associations. Other strengths of our study include the population-based design, the estimation of folate intake in a population of nonusers of alcohol and vitamin supplements, and the large sample size that facilitated examination of modifying effects.
In summary, we found that, although there was no overall relationship between MTHFR genotype and breast cancer risk, women with low intake of folate and who are homozygous for the MTHFR 677T polymorphism may be at substantially increased risk for breast cancer. Our data also suggest this association may be further modified by vitamin B12, vitamin B6, and methionine intake. This study adds support to the literature that one-carbon metabolism and MTHFR polymorphisms have a role in carcinogenesis and may be important in breast carcinogenesis.
|
Footnotes |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Requests for reprints: Wei Zheng, Center for Health Services Research, Vanderbilt University Medical Center, Nashville, TN 37232-8300. Phone: (615) 936-0682; Fax: (615) 936-1269 E-mail: wei.zheng{at}vanderbilt.edu
Received 8/ 8/03; revised 9/15/03; accepted 9/26/03.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  S. Beetstra, G. Suthers, V. Dhillon, C. Salisbury, J. Turner, M. Altree, R. McKinnon, and M. Fenech Methionine-Dependence Phenotype in the de novo Pathway in BRCA1 and BRCA2 Mutation Carriers with and without Breast Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2565 - 2571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Inoue, K. Robien, R. Wang, D. J. Van Den Berg, W.-P. Koh, and M. C. Yu Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study Carcinogenesis, October 1, 2008; 29(10): 1967 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Suzuki, K. Matsuo, K. Hirose, A. Hiraki, T. Kawase, M. Watanabe, T. Yamashita, H. Iwata, and K. Tajima One-carbon metabolism-related gene polymorphisms and risk of breast cancer Carcinogenesis, February 1, 2008; 29(2): 356 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Xu, M. D. Gammon, H. Zhang, J. G. Wetmur, M. Rao, S. L. Teitelbaum, J. A. Britton, A. I. Neugut, R. M. Santella, and J. Chen Polymorphisms of one-carbon-metabolizing genes and risk of breast cancer in a population-based study Carcinogenesis, July 1, 2007; 28(7): 1504 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. L. Stevens, M. L. McCullough, A. L. Pavluck, J. T. Talbot, H. S. Feigelson, M. J. Thun, and E. E. Calle Association of Polymorphisms in One-Carbon Metabolism Genes and Postmenopausal Breast Cancer Incidence Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1140 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-H. Xu, M. J. Shrubsole, Y.-B. Xiang, Q. Cai, G.-m. Zhao, Z.-x. Ruan, J.-r. Cheng, W. Zheng, and X. O. Shu Dietary Folate Intake, MTHFR Genetic Polymorphisms, and the Risk of Endometrial Cancer among Chinese Women Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 281 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Larsson, E. Giovannucci, and A. Wolk Folate and Risk of Breast Cancer: A Meta-analysis J Natl Cancer Inst, January 3, 2007; 99(1): 64 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lewis, R. M. Harbord, R. Harris, and G. D. Smith Meta-analyses of Observational and Genetic Association Studies of Folate Intakes or Levels and Breast Cancer Risk. J Natl Cancer Inst, November 15, 2006; 98(22): 1607 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. N. Martin, J. E. Olson, J. N. Ingle, R. A. Vierkant, Z. S. Fredericksen, V. S. Pankratz, Y. Wu, D. J. Schaid, T. A. Sellers, and R. M. Weinshilboum Methylenetetrahydrofolate Reductase Haplotype Tag Single-Nucleotide Polymorphisms and Risk of Breast Cancer. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2322 - 2324. [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Chou, M.-H. Wu, J.-C. Yu, M.-S. Lee, T. Yang, H.-L. Shih, T.-Y. Wu, and C.-A. Sun Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case-control study in Taiwan Carcinogenesis, November 1, 2006; 27(11): 2295 - 2300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E Gabriel, J. W Crott, H. Ghandour, G. E Dallal, S.-W. Choi, M. K Keyes, H. Jang, Z. Liu, M. Nadeau, A. Johnston, et al. Chronic cigarette smoking is associated with diminished folate status, altered folate form distribution, and increased genetic damage in the buccal mucosa of healthy adults. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 835 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lajous, E. Lazcano-Ponce, M. Hernandez-Avila, W. Willett, and I. Romieu Folate, vitamin b6, and vitamin B12 intake and the risk of breast cancer among mexican women. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 443 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Shrubsole, Y.-T. Gao, Q. Cai, X. O. Shu, Q. Dai, F. Jin, and W. Zheng MTR and MTRR Polymorphisms, Dietary Intake, and Breast Cancer Risk. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 586 - 588. [Full Text] [PDF]
|
|
|
|
|
|
C. Justenhoven, U. Hamann, C. B. Pierl, S. Rabstein, B. Pesch, V. Harth, C. Baisch, C. Vollmert, T. Illig, T. Bruning, et al. One-Carbon Metabolism and Breast Cancer Risk: No Association of MTHFR, MTR, and TYMS Polymorphisms in the GENICA Study from Germany Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 3015 - 3018. [Full Text] [PDF]
|
|
|
|
|
|
J. Kotsopoulos, A. Medline, R. Renlund, K.-J. Sohn, R. Martin, S. W. Hwang, S. Lu, M. C. Archer, and Y.-I. Kim Effects of dietary folate on the development and progression of mammary tumors in rats Carcinogenesis, September 1, 2005; 26(9): 1603 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Li, M. Ahmed, Y. Li, L. Jiao, T.-H. Chou, R. A. Wolff, R. Lenzi, D. B. Evans, M. L. Bondy, P. W. Pisters, et al. 5,10-Methylenetetrahydrofolate Reductase Polymorphisms and the Risk of Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1470 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Friso, D. Girelli, E. Trabetti, O. Olivieri, P. Guarini, P. F. Pignatti, R. Corrocher, and S.-W. Choi The MTHFR 1298A>C Polymorphism and Genomic DNA Methylation in Human Lymphocytes Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 938 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Quinlivan, S. R. Davis, K. P. Shelnutt, G. N. Henderson, H. Ghandour, B. Shane, J. Selhub, L. B. Bailey, P. W. Stacpoole, and J. F. Gregory III Methylenetetrahydrofolate Reductase 677C->T Polymorphism and Folate Status Affect One-Carbon Incorporation into Human DNA Deoxynucleosides J. Nutr., March 1, 2005; 135(3): 389 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, M. D. Gammon, W. Chan, C. Palomeque, J. G. Wetmur, G. C. Kabat, S. L. Teitelbaum, J. A. Britton, M. B. Terry, A. I. Neugut, et al. One-Carbon Metabolism, MTHFR Polymorphisms, and Risk of Breast Cancer Cancer Res., February 15, 2005; 65(4): 1606 - 1614. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research |
